Organovo (NASDAQ:ONVO) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of Organovo (NASDAQ:ONVO) in a report issued on Sunday. The brokerage issued a sell rating on the medical research company’s stock.

Organovo Price Performance

Organovo stock opened at $1.27 on Friday. The firm’s 50 day moving average price is $0.38 and its 200-day moving average price is $0.44. Organovo has a 1 year low of $0.32 and a 1 year high of $1.83. The stock has a market cap of $22.17 million, a P/E ratio of -1.49 and a beta of 0.54.

Organovo (NASDAQ:ONVO) last announced its quarterly earnings results on Wednesday, February 19th. The medical research company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.02. Organovo had a negative net margin of 10,151.64% and a negative return on equity of 346.26%. The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.05 million. As a group, equities analysts expect that Organovo will post -0.77 EPS for the current year.

Organovo Company Profile

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.